Estrella Immunopharma Beat Consensus Estimates

Estrella Immunopharma (ESLA) reported a loss of $0.05 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.09 per share. The company beat consensus estimates by 44.44%.

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The company's lead product candidate includes EB103 and EB104. Estrella Immunopharma Inc., formerly known as TradeUP Acquisition Corp., is based in NEW YORK.